Aster DM Quality Care Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Strong standalone quarter, merger synergies still ahead: Aster DM and Quality Care each delivered 19–22% standalone revenue growth with margin expansion, while the merger closed July 1 and synergy realization has not yet begun.
• Volume-led growth with complexity uplift: Patient throughput rose 16% and ARPP IP climbed 10%, driven by Centres of Excellence, robotics (up ~80% YoY), joint replacements (+39%), and transplants (+19%).
• Greenfield execution is a proven strength: The Kasaragod facility broke even within nine months of opening, and the Nagercoil hospital reached a ~₹180 Cr run rate with EBITDA near 30% inside two years.
• MVT is scaling fast off a small base: Medical value travel revenue grew 62% YoY, and management targets double-digit share of overall revenue over the next couple of years, powered by structured sales teams and word-of-mouth from 0.8 crore annual patients.
• What to watch next quarter: Whether the merged entity begins to show early synergy traction, the pace of occupancy gains at the new Whitefield Women & Children block, and any further detail on the new India cluster structure and brand strategy.

Merger Integration & Synergies

• Merger effective, integration just starting: The merger became effective July 1, 2026, with a #GOGREATER celebration across over 45,000 people and zero operational disruption; Q1 results are reported on a proforma basis and reflect entirely independent operations with no cohesive working between the two entities.
• 10-point synergy wheel yet to turn: Management reiterated its commitment to 10–15% incremental EBITDA from synergies (₹150–200 Cr on the FY24 proforma base) and expects significant results this financial year onwards, annualizing into next year.
• New India structure being finalized: Three India CEOs have been appointed, dividing the network into clusters (parts of Kerala plus Maharashtra; another Kerala segment plus Karnataka; Andhra, Telangana, Central, and part of East), with a matrixed overlay of clinical specialty leaders for oncology and cardiology. Management declined to disclose specific cluster compositions, saying the structure is still being refined.
• Brand convergence deferred: Management called the question premature, noting work has started on creating a company-level brand but will return with details in due course.

Alisha Moopen: "Just getting to this merger itself has been a Herculean task for us, but now making sure we are able to kind of go from that 1 + 1 = 11 is really the goal."

Standalone Operating Performance

• Aster DM standalone: Revenue grew 22% YoY with EBITDA up 29% and margin expanding 117 bps; volume-led with total patient throughput up 16% and ARPP IP up 10%, the latter supported by case-mix improvement from Centres of Excellence and robotic cases. Normalised PAT rose 39% YoY to ~₹125 Cr, with the ₹114 Cr exceptional item entirely merger-related. ROCE improved ~190 bps to 22.6%.
• Quality Care standalone: Revenue grew 19% YoY with EBITDA up 32% and margin expanding 216 bps to 23.2%; occupancy jumped 656 bps to 65.4%, and ARPP IP reached ~₹144k on deeper clinical mix and better payor mix.
• Kerala recovery: After a 5% degrowth in Q4 FY25, Kerala delivered 25% revenue growth (20% ex-Kasaragod) driven by volumes (IP +16%, OP +19%), following leadership changes and building a less people-dependent system.
• Karnataka turnaround: Growth accelerated from single digits to 16% with 5–6% volume growth, attributed to doctor hiring after attrition in the first two or three quarters of FY26; 18+ doctors were added in Bangalore in Q1, and all three Bangalore hospitals hit their highest-ever revenue in June. A general surgery team that left eight or nine months ago returned four months back.
• Medcity milestone: Medcity crossed ₹100 Cr of revenue in two separate months within Q1.

Maturity Framework & Asset Progression

• HITEC graduated to mature: Now above 25% EBITDA and JCI accredited, having moved out of the focus category a couple of years ago.
• Kasaragod broke even in nine months: Opened October 2025, achieved 2–3% EBITDA by June 2026, demonstrating greenfield execution speed.
• Nagercoil ramp: Opened 18–20 months ago, turned profitable in four months, now at a ~₹180 Cr revenue run rate with EBITDA closer to 30%.
• Stated maturity goal: Get every asset to mature status (25% EBITDA), while shrinking time-to-profitability for new hospitals.

Medical Value Travel

• 62% YoY growth, low base effect in play: Growth attributed to addition of new geographies, capability building with dedicated teams and resources, structured sales teams, CRM and lead tracking, digital interventions including website integration, and strong clinical outcomes generating word-of-mouth referrals.
• Targeting double-digit revenue share: Management expects MVT to continue growing faster than peers and aims to move from mid-single digit to double-digit share of overall revenue over the next couple of years.
• Flywheel from patient volume: The base of 0.2 Cr patients per quarter (0.8 Cr per year) returning happy and generating referrals is cited as the core growth engine.

Varun Khanna: "When you have 0.2 crore patients a quarter, 0.8 crore patients a year, come back to you, go back happy, they talk about it. When they talk about it, we get more patients. It's simple as that."

Clinical Complexity & Specialty Build-Out

• Robotics, joints, transplants driving case mix: Robotics volumes grew ~80% YoY, joint replacements +39%, transplants +19%, enabled by investment in medical technology and strengthening clinical skills across the network.
• Oncology as a big brownfield play: Investing in oncology for Tier 2 and Tier 3 cities, which is accretive on ARPOB, complexity, and patient load while delivering care closer to home.
• Cardiology scale: Management stated the group would be, if not the top, maybe top two on cardiology volume in India, and it remains a very big focus.
• Critical care readiness: Ensuring every hospital is equipped for critical care with multiple specialties and doctors available throughout day and night.
• Clinical talent synergy opportunity: Extension of complex programs (e.g., deep brain stimulation from Kochi, liver transplant teams) across the network to leverage clinical talent across multiple hospitals.
• Clinical milestones in Q1: India's first Robotic Hepatic Artery Infusion therapy for non-curable liver metastases; Kerala's first transcatheter Fontan procedure at Kochi; high-risk multidisciplinary surgery for Stage IV colon cancer at Nagercoil.

Varun Khanna: "I don't see it as gaps. I see this as a continuous upgrade that I think the industry will have to go through over multiple years."

Capacity Expansion Pipeline

• 4,170+ beds over 3–4 years: Clear roadmap to take total capacity beyond 15,000 beds, with 53% brownfield-led and capital deployment focused on deepening presence across core Southern, Central, and Eastern regions.
• Recently commissioned: A 159-bed Aster Women & Children block at Aster Whitefield, Bengaluru, commissioned in April 2026 and already seeing strong patient traction.
• Near-term openings: Raipur cancer center inaugurating in the middle of this month (Q1 FY27); Aster Capital Trivandrum operational in H2 FY27, most probably January; Hyderabad hospital operational around April 2027 (beginning of FY28); Sarjapur Phase I (A block) in H2 FY28.
• QCIL projects by 2028: Bhubaneswar (big project), Kottayam capacity addition, Nagercoil bed addition, Banjara Hills bed addition, and smaller bed adds at Nampally and Shifa. Management declined to give a complete hospital-wise breakdown, directing instead to total quantum of brownfield and greenfield beds.

Guidance & Commitments

Key Metrics